COST-EFFECTIVENESS OF CELECOXIB VERSUS IBUPROFEN AND NAPROXEN IN PATIENTS WITH OSTEOARTHRITIS IN UNITED ARAB EMIRATES AND SAUDI ARABIA BASED ON RESULTS FROM THE PRECISION TRIAL

被引：0
|
作者：
Ahmed, O. H. [1 ]
Chirikov, V [2 ]
Walker, C. [3 ]
Stephens, J. M. [2 ]
Schepman, P. [4 ]
Chambers, R. [5 ]
Bakir, M. [6 ]
Poorman, G. [7 ]
Haider, S. [8 ]
机构：
[1] Mouwsat Hosp Dammam, Dammam, Saudi Arabia
[2] Pharmerit Int, Bethesda, MD USA
[3] Pfizer, Tadworth, England
[4] Pfizer, New York, NY USA
[5] Pfizer Inc, Collegeville, PA USA
[6] Pfizer, Jeddah, Saudi Arabia
[7] Upjohn Pfizer Inc, New York, NY USA
[8] Pfizer Inc, Groton, CT 06340 USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDG10
引用
收藏
页码：S130 / S130
页数：1
相关论文
共 50 条
  • [1] Evaluating the Cost-Effectiveness of Celecoxib versus Ibuprofen and Naproxen in Patients with Osteoarthritis in United Arab Emirates Based on the PRECISION Trial
    Chirikov, Viktor V.
    Walker, Chris
    Stephens, Jennifer M.
    Schepman, Patricia
    Chambers, Richard
    Bakir, Mahmoud
    Poorman, Gregory W.
    Haider, Seema
    Farghaly, Mohammed
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2021, 13 : 409 - 420
  • [2] Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial
    Obeid, Slayman
    Libby, Peter
    Husni, Elaine
    Wang, Qiuqing
    Wisniewski, Lisa M.
    Davey, Deborah A.
    Wolski, Katherine E.
    Xia, Feng
    Bao, Weihang
    Walker, Chris
    Ruschitzka, Frank
    Nissen, Steven E.
    Luescher, Thomas F.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (06) : 611 - 621
  • [3] The cost-effectiveness of celecoxib versus diclofenac in elderly patients with osteoarthritis of the hip or knees
    Jacobson, L
    Henriksson, F
    Ringertz, B
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 522 - 522
  • [4] IDENTIFICATION AND MANAGEMENT OF PATIENTS WITH STATIN INTOLERANCE IN SAUDI ARABIA AND THE UNITED ARAB EMIRATES: COMPARISON OF RESULTS FROM A CLINICIAN SURVEY
    Rosenson, R. S.
    Gandra, S. R.
    McKendrick, J.
    Dent, R.
    Wieffer, H.
    Catapano, A. L.
    Oh, P.
    Hovingh, G. K.
    Stroes, E.
    VALUE IN HEALTH, 2016, 19 (07) : A664 - A664
  • [5] Cardiorenal Risks of Celecoxib, Naproxen or Ibuprofen in Arthritis Patients : A Sub-Anaylsis From the PRECISION Trial
    Obeid, Slayman
    Libby, Peter
    Husni, M. Elaine
    Pfeffer, Marc A.
    Wisniewski, Lisa M.
    Wolski, Katherine E.
    Wang, Qiuqing
    Nissen, Steven E.
    Luscher, Thomas F.
    CIRCULATION, 2017, 136
  • [6] THE COST-EFFECTIVENESS OF IVF TREATMENTS GONAL-F VERSUS HP -HMG IN THE UNITED ARAB EMIRATES (UAE)
    Elkalyoubi, M.
    Garg, N.
    Farag, Eladly T.
    Fakih, A.
    Jain, R.
    Madkour, W.
    Noah, B.
    Prasanna, R.
    Sayed, W.
    Wadie, G.
    Zaheer, H.
    van Gils, C.
    VALUE IN HEALTH, 2017, 20 (09) : A522 - A522
  • [7] Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM( Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial
    Ruschitzka, Frank
    Borer, Jeffrey S.
    Krum, Henry
    Flammer, Andreas J.
    Yeomans, Neville D.
    Libby, Peter
    Luscher, Thomas F.
    Solomon, Daniel H.
    Husni, M. Elaine
    Graham, David Y.
    Davey, Deborah A.
    Wisniewski, Lisa M.
    Menon, Venu
    Fayyad, Rana
    Beckerman, Bruce
    Iorga, Dinu
    Lincoff, A. Michael
    Nissen, Steven E.
    EUROPEAN HEART JOURNAL, 2017, 38 (44) : 3282 - 3292
  • [8] The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia
    Nasef, Sherif A.
    Shaaban, A. Aziz
    Mould-Quevedo, Joaquin
    Ismail, Tarek A.
    HEALTH ECONOMICS REVIEW, 2015, 5
  • [9] The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia
    Sherif A Nasef
    A. Aziz Shaaban
    Joaquin Mould-Quevedo
    Tarek A Ismail
    Health Economics Review, 5
  • [10] Cost-effectiveness of eletriptan versus zolmitriptan: Results from a randomized controlled trial
    Mullins, CD
    Healey, PJ
    Mychaskiw, M
    Meng, F
    Weis, KA
    VALUE IN HEALTH, 2005, 8 (03) : 318 - 318
12345